iSpecimen Inc. Accretion (Amortization) of Discounts and Premiums, Investments
iSpecimen Inc. (ISPC) reported Accretion (Amortization) of Discounts and Premiums, Investments of $28.98 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2024-11-07
- iSpecimen Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-06-30 was $1.55K.
- iSpecimen Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2024-03-31 was $27.43K.
- iSpecimen Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2023-12-31 was $30.12K.
- iSpecimen Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $177.29K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.55K derived: sum of 2 quarters · filed 2024-11-07 | $28.98K 10-Q · filed 2024-11-07 | $59.10K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $1.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $28.98K 10-Q · filed 2024-08-06 | $59.10K derived: sum of 3 quarters · filed 2024-08-06 | $108.40K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $27.43K 10-Q · filed 2024-05-07 | $57.55K derived: sum of 2 quarters · filed 2024-05-07 | $106.85K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-12-31 | $30.12K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $79.42K derived: sum of 2 quarters · filed 2024-11-07 | $177.29K 10-K · filed 2024-03-13 | |
| 2023-09-30 | $49.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $147.17K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $97.87K 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |